Future cardiology最新文献

{"title":"Accuracy and correlation of bed and standing scale weights in monitoring volume status in heart failure patients.","authors":"Devin Skoll, Phillip Abarca, Vu Pham, Anushka Das, Clark Mantini, Han Tun, Helga Van Herle, Ajay Vaidya, Aaron M Wolfson, Michael W Fong","doi":"10.1080/14796678.2024.2340919","DOIUrl":"10.1080/14796678.2024.2340919","url":null,"abstract":"<p><p><b>Introduction:</b> Accurate volume status monitoring is crucial for effective diuretic therapy in patients with acute decompensated heart failure (ADHF). While guidelines recommend daily standing body weight measurement as an indicator of volume status, bed scales are commonly used in healthcare facilities.<b>Methods:</b> A method-comparison design was used to compare bed and standing scale weights among adults hospitalized with ADHF at Los Angeles County-University of Southern California Medical Center between March and April 2023.<b>Results & Conclusion:</b> Among 51 weight pairs from 43 participants, a clinically significant mean difference of 1.42 ± 1.18 kg was observed, exceeding the recommended threshold. Inaccuracies, with 71% showing differences >0.6 kg, highlight potential fluid management errors when relying on bed scales in ADHF hospitalizations.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"389-393"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140859977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges and advances in device-related thrombus in left atrial appendage occlusion.","authors":"Takamasa Tanaka, Kenji Kawai, Christopher R Ellis, Mukta Srivastava, Rika Kawakami, Takao Konishi, Tatsuya Shiraki, Teruo Sekimoto, Renu Virmani, Aloke V Finn","doi":"10.1080/14796678.2024.2363063","DOIUrl":"10.1080/14796678.2024.2363063","url":null,"abstract":"<p><p>Oral anticoagulation therapy (OAC) is a mainstay for mitigating stroke and other embolic events in patients with atrial fibrillation (AF). Despite the demonstrated efficacy of OAC in reducing events, many patients are unable to tolerate OAC due to bleeding risks. Left atrial appendage occlusion (LAAO) devices were developed as implantable technologies to moderate stroke risk in patients with intolerance to OAC. Despite clinical data supporting near-comparable protection against thromboembolic events with OAC, device-related thrombus formation has emerged as a critical complication following LAAO that remains a potential limitation to the safety and efficacy of LAAO. Improved biocompatibility of LAAO devices with fluoropolymers, a well-established stent-coating technology used to reduce thrombus formation and promote endothelialization, may optimize outcomes after LAAO.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"343-358"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitral valve replacement in young patients: review and current challenges.","authors":"Fadi Hage, Ali Hage, Manuel R Cervetti, Michael W A Chu","doi":"10.1080/14796678.2024.2343592","DOIUrl":"10.1080/14796678.2024.2343592","url":null,"abstract":"<p><p>Mitral valve repair is the ideal intervention for mitral valve disease with excellent long-term survival comparable to the age-matched general population. When the mitral valve is not repairable, mechanical prostheses may be associated with improved survival as compared with biological prostheses. Newer mechanical and biological valve prostheses have the potential to improve outcomes following mitral valve replacement in young patients. Patients presenting for mitral valve surgery after failed transcatheter mitral valve-in-valve have high rates of postoperative mortality and morbidity, exceeding those seen with reoperative mitral valve surgery, which poses issues in young patients who have a higher cumulative incidence of reintervention.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"409-417"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457673/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141563147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ITIH4 is a predictor for coronary thrombus in coronary arteriography patients.","authors":"Lei Tian, Su Zhao, Ruiyan Zhang","doi":"10.1080/14796678.2024.2377924","DOIUrl":"10.1080/14796678.2024.2377924","url":null,"abstract":"<p><p><b>Aim:</b> To explore potential value of inter-alpha-trypsin inhibitor heavy chain-4 (ITIH4) for coronary artery disease (CAD) diagnosis.<b>Patients & methods:</b> We recruited the patients who received coronary arteriography (CAG) examination. The enzyme-linked immunosorbent assay was used to detect plasma ITIH4.<b>Results:</b> ITIH4 level was lower expression in CAD patients than that in patients of control group, and was negatively correlated with C-reactive protein (CRP). ITIH4 level is no differences between ST-elevated myocardial infarction (STEMI) and non-ST-elevated myocardial infarction (NSTEMI) patients. However, its expression was significantly correlated with D-Dimer and thrombin time, and the logistic analysis confirmed predictive value of ITIH4 for visible thrombus in coronary.<b>Conclusion:</b> ITIH4 may be a useful biomarker in CAD diagnosis, and to predict visible thrombus in coronary.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"547-554"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute coronary syndrome due to coronary vasospasm: a case report.","authors":"Andy Wang, Juliet Meir, Aaqib Malik, Tzvi Fishkin, Subo Dey, Julio A Panza, Syed Haidry","doi":"10.1080/14796678.2024.2392995","DOIUrl":"10.1080/14796678.2024.2392995","url":null,"abstract":"<p><p>Coronary vasospasm can lead to decreased cardiac perfusion and result in acute coronary syndrome. Here is a case of a 49-year-old man presented to the emergency department with epigastric pain and nausea with normal initial electrocardiogram. However, 6 h later, the patient experienced severe chest pain prompting a repeat electrocardiogram demonstrating inferior ST-segment elevation with troponin I levels peaked at 1.2 ng/ml (normal range: 0.00-0.02 ng/ml). Coronary angiography revealed angiographic stenosis in the left circumflex territory of a left dominant system which resolved with intracoronary nitroglycerin administration indicating ischemia with nonobstructive coronary arteries secondary to coronary vasospasm. He was discharged on isosorbide mononitrate and amlodipine therapy and had no recurrence of symptoms during follow-up.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"613-618"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11520529/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of long-term tafamidis treatment on quality of life in people with transthyretin amyloid cardiomyopathy (ATTR-CM): A plain language summary.","authors":"Martha Grogan, Margot K Davis, Maria G Crespo Leiro, Marla B Sultan, Balarama Gundapaneni, Franca Stedile Angeli, Mazen Hanna","doi":"10.1080/14796678.2024.2391250","DOIUrl":"10.1080/14796678.2024.2391250","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This summary explains some results of a study called ATTR-ACT and its ongoing long-term extension study that were published in the <i>European Journal of Heart Failure</i>. The purpose of ATTR-ACT was to find out if a drug called tafamidis is an effective treatment for people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). People took tafamidis or placebo for up to 2.5 years in ATTR-ACT (the initial study). A placebo looks like the study medicine but does not contain any active ingredients. After people completed the initial study, they could take part in the extension study. An extension study allows people to continue receiving treatment after the original clinical study ends and helps researchers understand how well a treatment works over a longer time period. This extension study allows people to receive tafamidis for up to an additional 5 years. People who took placebo in the initial study now receive tafamidis. People who took tafamidis in the initial study continue tafamidis treatment. Researchers looked at changes in peoples' ability to enjoy life ('quality of life') and heart failure symptoms since they started ATTR-ACT. Results are available for the first 2.5 years of the extension study.</p><p><strong>What are the key takeaways?: </strong>During the initial study, there was less worsening of quality of life and heart failure symptoms in people who took tafamidis compared to people who took placebo. In the extension study, quality of life and heart failure symptoms were maintained or nearly maintained in people who took tafamidis in the initial study. In people who started tafamidis in the extension study, quality of life and heart failure symptoms continued to worsen, but the worsening slowed down.</p><p><strong>What were the main conclusions reported by the researchers?: </strong>Tafamidis slows the worsening of quality of life and heart failure symptoms in people with ATTR-CM. People with ATTR-CM should start treatment early to receive the most benefit.<b>Clinical Trial Registration:</b> NCT01994889 (ATTR-ACT) (ClinicalTrials.gov).</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"595-603"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524204/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142283916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Second-generation everolimus-eluting intracoronary stents: a comprehensive review of the clinical evidence.","authors":"Ridhima Goel, Alessandro Spirito, Michael Gao, Birgit Vogel, Deborah N Kalkman, Roxana Mehran","doi":"10.2217/fca-2023-0092","DOIUrl":"10.2217/fca-2023-0092","url":null,"abstract":"<p><p>Percutaneous coronary intervention with implantation of second-generation drug-eluting stents (DES) has emerged as a mainstay for the treatment of obstructive coronary artery disease given its beneficial impact on clinical outcomes in these patients. Everolimus-eluting stents (EES) are one of the most frequently implanted second-generation DES; their use for the treatment of a wide range of patients including those with complex coronary lesions is supported by compelling evidence. Although newer stent platforms such as biodegradable polymer DES may lower local vessel inflammation, their efficacy and safety have not yet surpassed that of Xience stents. This article summarizes the properties of the Xience family of EES and the evidence supporting their use across diverse patient demographics and coronary lesion morphologies.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"103-116"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139642022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of comorbidities and sociodemographic predictors on pneumococcal vaccination coverage in adults with coronary heart disease.","authors":"Saint-Martin Allihien, Sammudeen Ibrahim, Favour Markson, Walter Y Agyeman, Setri Fugar, Onoriode Kesiena","doi":"10.2217/fca-2023-0095","DOIUrl":"10.2217/fca-2023-0095","url":null,"abstract":"<p><p><b>Aim:</b> Coronary heart disease (CHD) increases the risk of adverse outcomes from invasive pneumococcal disease. <b>Methods:</b> Using the 2020 and 2021 data from the national health interview survey, we identified adults with CHD. Chi-square analysis and logistic regression were used to examine factors that influence vaccination status. <b>Results:</b> There were 2675 participants aged 41 and above with CHD. Participants were predominantly white people (82.5%) and males (60.1%). The odds of receiving the pneumococcal vaccine increased with stepwise increase in comorbidities from 1 to 2 and from 2 to 3. Among individuals with ≥2 comorbidities, black people were less likely to be vaccinated compared with white people. <b>Conclusion:</b> Pneumococcal vaccine uptake among adults with CHD is determined by cumulative comorbidities and ethnicity.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"11-19"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138800822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Organizational challenges for partial heart transplantation.","authors":"Vincent S Alexander, Andrew D Vogel, Zachary T Silvano, Herra Javed, Alekhya Mitta, Taufiek Konrad Rajab","doi":"10.1080/14796678.2024.2404775","DOIUrl":"10.1080/14796678.2024.2404775","url":null,"abstract":"<p><p>Partial heart transplantation (PHT) has emerged as a new treatment strategy to correct unrepairable heart valve dysfunction in pediatric patients. PHT selectively replaces the dysfunctional components of the recipient's heart and spares the native ventricles. As a result, the transplant biology of PHTs differs from heart transplants. Notably, donor hearts that are unsuitable for whole heart transplantation can be used, graft preservation can be prolonged and immunosuppression levels can be lowered. These nuances of PHT transplant biology have important implications for organizational aspects of PHT clinical application.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"719-728"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new goal for secondary prevention of cardiovascular diseases: the reduction of neutrophil count.","authors":"Stefano De Servi, Antonio Landi","doi":"10.1080/14796678.2024.2384239","DOIUrl":"10.1080/14796678.2024.2384239","url":null,"abstract":"","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"517-519"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}